Bianca C Creanza

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
INTRODUCTION Currently available drugs against Alzheimer's disease (AD) target cholinergic and glutamatergic neurotransmissions without affecting the underlying disease process. Putative disease-modifying drugs are in development and target β-amyloid (Aβ) peptide and tau protein, the principal neurophatological hallmarks of the disease. Areas covered: Phase(More)
  • 1